RZ-001 Gene Therapy Shows >6-Month Disease Control in rGBM; 10 Patients Treated with No Safety Concerns

For the thousands of patients diagnosed with recurrent glioblastoma each year, standard treatments offer limited hope, with median survival often under a year. The interim data from Rznomics’ RZ-001 trial, however, suggests that a novel RNA editing approach might finally move the needle, showing disease control extending beyond six months in some patients—a meaningful signal in a notoriously aggressive cancer.

Rznomics Inc., a South Korean biopharma specializing in RNA-based gene therapies, unveiled interim clinical data for its lead candidate RZ-001 (taspitimagene advec) in recurrent glioblastoma (rGBM) at the Asian Society for Neuro-Oncology Annual Meeting (ASNO 2026) in Kanazawa, Japan. The presentation, delivered by Dr. Chae-Yong Kim of Seoul National University Bundang Hospital, marked the first public disclosure of human data from the Phase 1/2a trial. With 20 patients screened and 10 enrolled and treated to date, the results signal a potentially new class of therapy for one of the deadliest brain cancers.

“

Chae-Yong Kim of Seoul National University Bundang Hospital, marked the first public disclosure of human data from the Phase 1/2a trial.

Recurrent glioblastoma carries a dismal prognosis, with median overall survival typically under one year despite maximal surgical resection, radiation, and temozolomide chemotherapy. The tumor's infiltrative nature, high mutational burden, and immunosuppressive microenvironment have thwarted most targeted and immuno-oncology agents in late-stage trials. Recent failures of checkpoint inhibitors and vaccine approaches have underscored the need for mechanisms that bypass conventional immune evasion. RZ-001, an RNA trans-splicing ribozyme, attempts to do just that: instead of correcting DNA, it repairs the cancer's messenger RNA inside tumor cells, causing them to express a cytotoxic gene that induces apoptosis. Because the ribozyme is designed to recognize tumor-specific RNA sequences, off-target effects are theoretically minimized.

The interim safety analysis is notably clean. No dose-limiting toxicities (DLTs) have been reported, and no treatment-related adverse events of Grade 4 or higher were observed. The investigators attributed most reported mild/moderate events to underlying disease or typical glioblastoma comorbidities, suggesting that the therapy’s local, RNA-directed mechanism may avoid the systemic toxicities that often hinder gene or viral vector approaches. While the sample size is small — just 10 patients — the absence of unexpected safety signals in a heavily pretreated population is a meaningful milestone for a novel platform.

On the efficacy front, the data are early but provocative. Several patients experienced prolonged tumor recurrence inhibition and disease control exceeding six months. In a disease where radiographic progression often appears within weeks of standard therapy ending, a six-month or longer period of stable disease is a clinically relevant signal. Still, without control-arm data or mature overall survival figures, these observations remain hypothesis-generating. The Phase 1/2a trial is dose-escalating, and the company indicated that enrollment is ongoing to further explore the optimal biological dose.

The broader context of the RNA editing field adds weight to Rznomics' update. Other RNA editing companies have advanced siRNA, antisense oligonucleotides, and CRISPR-based RNA editors, but a ribozyme approach that trans-splices to replace defective RNA segments is relatively unique. RZ-001, if eventually approved, could open a new therapeutic category. However, path to market is steep: glioblastoma trials must demonstrate convincing improvement in overall survival or progression-free survival in randomized Phase 2/3 studies, and regulatory agencies will scrutinize long-term safety, especially potential integration or off-target effects.